EU-approved Cosentyx

BIOLOGICAL3 trials

Sponsors

Bio-Thera Solutions, Celltrion

Conditions

Healthy Male SubjectsPlaque Psoriasis

Phase 1

To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

CompletedNCT07054970

CelltrionHealthy Male Subjects

Start: 2024-01-12End: 2024-09-06Updated: 2025-07-08

Phase 3

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

CompletedNCT05377944

Bio-Thera SolutionsPlaque Psoriasis

Start: 2022-10-26End: 2024-12-10Updated: 2025-04-23

A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis

Active, not recruitingNCT06630559

CelltrionPlaque Psoriasis

Start: 2025-05-26End: 2026-10-01Updated: 2026-02-23

Related Papers

Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I study.

2026-02-10